INT274417

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 12
Disease Relevance 6.99
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Zfpm2) intracellular (Zfpm2) DNA binding (Zfpm2)
nucleic acid binding transcription factor activity (Zfpm2) transcription factor binding (Zfpm2) cytoplasm (Zfpm2)
Anatomy Link Frequency
hearts 3
epicardium 2
embryos 1
cardiomyocytes 1
Zfpm2 (Mus musculus)
Pain Link Frequency Relevance Heat
anesthesia 12 5.00 Very Low Very Low Very Low
isoflurane 12 5.00 Very Low Very Low Very Low
imagery 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Repression 96 100.00 Very High Very High Very High
Targeted Disruption 480 99.80 Very High Very High Very High
Heart Defects 24 99.08 Very High Very High Very High
Atrial Heart Septal Defects 12 98.28 Very High Very High Very High
Hyperplasia 12 94.76 High High
Ventricular Heart Septal Defects 84 93.60 High High
Cytomegalovirus Infection 84 62.64 Quite High
Disease 36 57.40 Quite High
Stress 12 52.76 Quite High
Congenital Anomalies 12 49.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
S., unpublished observations), it is likely that transgenic mice with low level miR-130a expression may also not develop cardiac malformations due to only modest reductions in FOG-2 protein levels.
Negative_regulation (reductions) of FOG-2 protein associated with targeted disruption
1) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.91 Pain Relevance 0
Since mice heterozygous for a disruption in the FOG-2 gene do not have any cardiac phenotype [18] and only express 50% of normal FOG-2 levels (G.
Negative_regulation (disruption) of FOG-2 gene
2) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.75 Pain Relevance 0
In the miR-130a transgenic embryos, FOG-2 levels should only be reduced in cardiomyocytes, since the ?
Negative_regulation (reduced) of FOG-2 in cardiomyocytes associated with targeted disruption
3) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.96 Pain Relevance 0
It is currently unclear how reduced cardiac FOG-2 levels lead to a thin ventricular wall, but the results presented in this report suggest that it is due to the loss of FOG-2 specifically in cardiomyocytes, rather than the endocardium or epicardium.
Negative_regulation (reduced) of FOG-2 in epicardium
4) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.70 Pain Relevance 0
We show that miR-130a is expressed in cardiomyocytes and when over-expressed during embryonic development, results in a down-regulation of FOG-2 protein levels and structural heart defects similar to those seen in mice deficient in FOG-2, thus suggesting that it may play a role in regulating cardiac development.


Negative_regulation (regulation) of FOG-2 protein in heart associated with heart defects
5) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.29 Pain Relevance 0
In the hearts of these mice, FOG-2 protein levels were reduced by as much as 80%.
Negative_regulation (reduced) of FOG-2 protein in hearts
6) Confidence 0.43 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2701631 Disease Relevance 0.28 Pain Relevance 0
We also used a gain of function approach to demonstrate miR-130a's role in mediating translational repression of FOG-2.
Negative_regulation (repression) of FOG-2 associated with repression
7) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.33 Pain Relevance 0
However, the thin compact zone seen in the miR-130a transgenic mice is similar to that seen in the FOG-2 deficient mice, suggesting that this phenotype may be due to reduced FOG-2 levels.
Negative_regulation (reduced) of FOG-2 associated with targeted disruption
8) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.72 Pain Relevance 0
It is currently unclear how reduced cardiac FOG-2 levels lead to a thin ventricular wall, but the results presented in this report suggest that it is due to the loss of FOG-2 specifically in cardiomyocytes, rather than the endocardium or epicardium.
Negative_regulation (loss) of FOG-2 in epicardium
9) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.67 Pain Relevance 0
Interestingly, as miR-130a levels peak in the neonate, FOG-2 protein levels decline (Fig. 1F).
Negative_regulation (decline) of FOG-2 protein
10) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.06 Pain Relevance 0
Three of four hearts examined showed significantly reduced FOG-2 protein levels (Fig. 5B).
Negative_regulation (reduced) of FOG-2 protein in hearts
11) Confidence 0.42 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.63 Pain Relevance 0
Further, quantitation of protein levels found that FOG-2 was reduced by 75 to 80% in half of the embryos examined (Figure 5C).
Negative_regulation (reduced) of FOG-2 in embryos
12) Confidence 0.42 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2701631 Disease Relevance 0.68 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox